This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

CompLaw: Pharma
3 December 2024
DoubleTree by Hilton Brussels CityBelgium
3 December 2024|DoubleTree by Hilton Brussels City, Belgium

The only European conference focusing specifically on competition law in the pharma sector.

Get the full picture in just 1 day... enforcement, mergers, Article 102, patents, FDI, FSR, disparagement, distribution challenges, as well as combination therapies and biosimilars - we have you covered!

Global Head of Legal Antitrust

Sandoz AG

The conference to attend

This is the conference to attend if you are a pharma competition lawyer.

Your essential 1-day update. Highlights for 2024 include:

Hear from the Regulators

Hear from Anna Vernet, Head of Unit, DG Competition, European Commission on their current priorities for the sector and ask your burning questions during the Q&A.

You will then have an opportunity to hear from representatives from key national competition authorities to ensure you are fully up to date with enforcement across Europe.

Mergers, FDI & FSR

Inspect the current approach to mergers, including where we are with Article 22 after the ECJ judgment in Illumina/ Grail and the use of Article 102 after TowerCast, as well as broader issues relating to innovation and below-threshold deals.

Then gain practical tips on how to manage multijurisdictional transactions in light of merger control, FDI & FSR considerations.

Article 102

Examine where we are with the EC’s update on draft Article 102 guidelines, what the Commission is trying to achieve and an update on recent excessive pricing decisions, exclusionary conduct, and rebates.

Combination Therapies

Discuss combination therapies, their challenges from a competition law perspective, and how the regulators are approaching them. What can the authorities do to facilitate greater entry of combination therapies into the market? Is there a need for a coordinated approach to combination therapies across EU?

Disparagement

Analyse the EC’s recent Vifor and Teva cases, how national regulators are approaching disparagement and what lessons can be learned for corporate compliance including promotional efforts, internal processes and codes of ethics.

Patents

Gain an update on recent EU and national developments including product hopping and 2nd generation products as well as the latest from the Unified Patent Court (UPC).

Connect with the pharma community!

Join us for a drinks reception to catch up with your peers and make new connections in an informal setting.

CompLaw: Pharma in numbers:

0

years as the leading review of competition law in the pharma sector

100+

Attendees

53%

in-house counsel & regulators joining the event

CPD Certification - 6.5 CPD Hours Available

Attendance at this conference may be used to claim CPD from your professional body. The number of hours, or points may vary from body to body. Upon request, we will supply you with a certificate of attendance to facilitate your CPD submission with your professional membership organisation.

Interested in getting involved?

Get in touch with us today to discuss a sponsorship and exhibition package that can help you demonstrate your knowledge and expertise, generate leads and put your brand in the spotlight.

For more information please contact Enes Duzen on Enes.Duzen@informa.com or call +44 (0) 20 8052 0469.